Disease Landscape and Forecast 인사이트

MARKET OUTLOOK The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The anticipated entry of first-in-UC oral therapies for the moderate to severe population,…

Patients with osteoporosis and osteopenia are at increased risk of suffering fractures. These fractures place a considerable burden on public health systems, and significant unmet need remains in…

Acute coronary syndrome (ACS)─an umbrella term that encompasses acute ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina─is a leading cause of…

In the past decade, TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen), as well as Janssen’s IL-12/23 inhibitor Stelara, have been leading the U.S. psoriasis biologics market. However, the…

The increase in oral oncolytics has fueled an increase in oncologist dispensing of drugs either from the physician office or from a pharmacy owned by the practice or hospital, as allowed by state…

The psoriasis market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12 and -23…

Despite the availability of multiple oral atypical antipsychotics in the United States, long-acting depot formulations of atypical antipsychotics offer a compelling advantage because of their less…

The hepatitis C virus (HCV) therapy market has been marked by tremendous growth, and the treatment landscape has undergone a rapid evolution with the launch of novel direct-acting antivirals (DAAs…

Market Outlook Osteoarthritis (OA) pain is an extremely prevalent type of chronic pain, affecting more than 30 million individuals in the United States, and is the second-largest segment of the…

The type 2 diabetes market is expanding rapidly, fueled by increasing prevalence and a wave of recent product launches. Sanofi’s Suliqua (lixisenatide/insulin glargine), Novo Nordisk’s Fiasp,…

Abstract: Owing to the large diagnosed prevalent population, relatively high rates of drug treatment across patients of all disease severities, and high rates of polypharmacy—particularly…

Although ESA biosimilars entered the European market a decade ago, their uptake varies from country to country, as well as by drug and manufacturer. While European …